PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a newly established biopharmaceutical company focused on advancing promising immuno-oncology therapeutics, announced today that it has entered into an exclusive worldwide license agreement with Albert Einstein College of Medicine (“Einstein”) and Memorial Sloan Kettering Cancer Center (“MSK”).
Under the terms of the license agreement with Einstein and MSK, Immune-Onc will acquire the exclusive global rights to develop and commercialize novel biotherapeutics with applications in cancer immunotherapy and other diseases. In addition, Immune-Onc and Einstein have entered into a multi-year research collaboration to discover and develop a new generation of biotherapeutics that modulate the immune system.
"Einstein is recognized globally as a premier medical institution focused on discovery and translation of innovative biomedical research to clinical applications. MSK is the world's oldest and largest private cancer center and is renowned for having successfully produced nine US FDA approved drugs,” commented Dr. Charlene Liao, Chief Executive Officer of Immune-Onc. “Immune-Onc is very pleased to license innovative biotherapeutic candidates from Einstein and MSK. We are honored to partner with world-class investigators at Einstein to provide new treatment options for cancer patients in the near future.”
About Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients. The company was founded in 2016 with headquarters in Palo Alto, California. www.immune-onc.com
